hVIVO Regulatory News (HVO)

For immediate release 07.00: 7 October 2014

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

BOARD CHANGE

Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human models of disease, is pleased to announce that James F. Winschel has been appointed with immediate effect as a Non-Executive Director of the Company and Chairman of the Audit Committee.

Jim retired in June 2014 as Executive Vice President at PAREXEL International Corporation ("PAREXEL"), a US publicly-traded healthcare services company (NASDAQ: PRXL) with $1.9 billion in annual service revenue. He previously served as Senior Vice President and Chief Financial Officer of PAREXEL from 2000 to 2013, with responsibility for directing all financial activities, during a period when PAREXEL's revenue grew by $1.5 billion, backlog increased by $4.5 billion and market capitalisation increased from $225 million to $2.7 billion.

Jim is currently a Director of Cambrex Corporation, a US company offering products, services and technologies to accelerate the development and commercialisation of small molecule therapeutics.

Jim previously spent five years at BTM Capital Corporation, a Bank of Tokyo-Mitsubishi Ltd. subsidiary, initially as Executive Vice President and Chief Financial Officer for three years from 1995 before being promoted to President, U.B. Vehicle Leasing, Inc. through 2000. Prior to these roles, he was the Vice President - Finance, Physician Services Division at Caremark International, Inc. for two years from 1993 and spent the previous four years at Whirlpool Financial Corporation (WFC), both as the Vice President & Managing Director, Commercial Financing Division and prior to that as the Vice President and Chief Financial Officer.

Earlier in his career, Jim worked for five years in various roles at General Electric Capital Corporation, in the Transportation and Industrial Financing Division and prior to that at General Electric Company for eleven years. Jim holds an MBA in Accounting and a BSc in Finance from Syracuse University in the USA.

Kym Denny, Chief Executive Officer, commented, "I am delighted to welcome Jim to Retroscreen's Board as a Non-Executive Director and as Chairman of the Audit Committee. Jim has an outstanding track record, having worked in various finance and other senior management roles for a range of major US companies including PAREXEL, a leading global CRO. We look forward to benefitting from his tremendous background and experience, as we continue to expand and deliver our ground-breaking hVIVO technology platform."

James Francis Winschel (65) is a director/ partner or has been a director/ partner of the following companies/ partnerships during the previous five years:

Mr Winschel holds no ordinary shares in the Company.

Save for the information disclosed above there is no other information to be disclosed on Mr Winschel under Schedule 2(g) of the AIM Rules.

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)

Graham Yeatman (FD)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing life sciences company based in the UK pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to discover and study new drugs and diagnostics. To date, Retroscreen has conducted over 35 clinical studies, involving more than 1800 volunteers for a range of leading industry, governmental and academic clients.